Certara, Inc. CERT
At closeNov 6, 2026, 4:07 PM EST
After hours · Nov 6, 4:07 PM ET
- YTD
- +36.78%
- 1 year
- +6.92%
- Market cap
- 1.84B
- Revenue (ttm)
- 412.03M
- Profit margin
- -15.61%
- EPS (ttm)
- -0.18
- Shares out
- 152.54M
- Forward P/E
- 30.78
- YTD return
- +36.78%
- 1-year return
- +6.92%
- Volume
- 4.87M
- Avg volume
- 2.57M
- Open
- 12.03
- Previous close
- 12.18
- Day's range
- 11.79 – 12.61
- 52-week range
- 4.45 – 12.61
- Analysts
- Buy
- Price target
- 9.17 (-23.9%)
- Earnings date
- Nov 5, 2026
ALL -26.01 (-68.30%)
Key statistics
- Enterprise value
- 1.94B
- PEG ratio
- 0.00
- Price / sales
- 4.46
- Price / book
- 1.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -9.30%
- Free cash flow
- 33.32M
- Total cash
- 214.93M
- Total debt
- 298.23M
- Return on equity
- -2.70%
- Short % of float
- 26.37%
- 50-day average
- 9.26
- 200-day average
- 7.30
Analyst view
Consensus: buy
- Target (low)
- 7.00
- Target (mean)
- 9.17
- Target (high)
- 12.00
- Strong buy0
- Buy4
- Hold9
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.09421.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.08656 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 0.0893 | 0.08 | -0.01 | -10.41% |
| May 11, 2026 | Mar 31, 2026 | 0.11 | 0.09 | -0.02 | -18.18% |
| Feb 26, 2026 | Dec 31, 2025 | 0.11 | 0.09 | -0.02 | -18.18% |
| Nov 6, 2025 | Sep 30, 2025 | 0.11 | 0.14 | +0.03 | +27.27% |
| Aug 6, 2025 | Jun 30, 2025 | 0.10 | 0.07 | -0.03 | -30.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 16, 2026 | Keybanc | main | Overweight | Overweight |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Sep 30, 2026 | UBS | down | Buy | Neutral |
| Aug 5, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- certara.com
News
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $12 
Certara, Inc. (CERT) Tops Q3 Earnings and Revenue Estimates 
Certara Q3 2026 Earnings Call Transcript 
Certara Narrows FY2026 Adj EPS Guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 Est; Revenue for 2026 FY is expected to be up by 2% to 3% YoY 
Certara Reports Third Quarter 2026 Financial Results 
Birchtech Files Brief in Federal Circuit Supporting the $78 Million Patent Infringement Judgment Against CERT Defendants 
Keybanc Maintains Overweight on Certara, Raises Price Target to $12 
TD Cowen Maintains Buy on Certara, Raises Price Target to $11 
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $9 
UBS Downgrades Certara to Neutral, Maintains Price Target to $10
Your note
Sign in to keep a note on CERT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASPBURY ROBERT | Officer | Stock Award(Grant) | Mar 31, 2026 | 332,442 |
| BROSHY ERAN | Chairman of the Board | Conversion of Exercise of derivative security | May 13, 2026 | 50,708 |
| CASHMAN JAMES E III | Chairman of the Board | Conversion of Exercise of derivative security | May 13, 2026 | 484,197 |
| COLLINS CYNTHIA | Director | Conversion of Exercise of derivative security | May 13, 2026 | 51,846 |
| CRANE ROSEMARY A | Director | Conversion of Exercise of derivative security | May 13, 2026 | 45,672 |
| FEEHERY WILLIAM F. | Chief Executive Officer | Purchase | Nov 10, 2025 | 2,360,770 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.34% | 18,818,180 | 226.76M | Jun 29, 2026 |
| Deerfield Management Company, L.P | 4.93% | 7,512,928 | 90.53M | Jun 29, 2026 |
| Haveli Investment Management LLC | 4.85% | 7,400,000 | 89.17M | Jun 29, 2026 |
| Jefferies Financial Group Inc. | 4.65% | 7,091,051 | 85.45M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.63% | 7,056,106 | 85.03M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 4.25% | 6,479,818 | 78.08M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 4.40% | 6,716,940 | 80.94M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.44% | 3,721,805 | 44.85M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.01% | 3,060,357 | 36.88M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.75% | 2,673,186 | 32.21M | Jun 29, 2026 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 1.44% | 2,195,407 | 26.45M | Jun 29, 2026 |
| WASATCH FUNDS TRUST-Wasatch Small Cap Value Fund | 1.37% | 2,097,321 | 25.27M | Sep 29, 2026 |